ESR1 and breast carcinoma: For example, tamoxifen and the aromatase inhibitors have proven highly effective in the prevention of estrogen receptor-positive (ER+) breast cancer in large-scale clinical trials (Fisher et al., 1998; Goss et al., 2011).